Oaklander welcomed the news of the approval of the new vaccine, saying that more adults should be vaccinated against shingles. In the United States alone, there are an estimated 1 million cases of shingles a year, and one in three people can expected to develop the condition during their lifetime.
6 brokerages have issued twelve-month price objectives for Arbutus Biopharma Corp's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $7.00 in the next year.
We are reiterating a Buy rating on the common stock of Tobira Therapeutics with an updated price target (intrinsic value) of $34.88 using sum-of-the parts, enterprise DCF method. Tobira Therapeutics (NASDAQ: TBRA) announced the one-year results of a Phase 2 (CENTAUR) clinical trial in patients with non-alcoholic steato-hepatitis (NASH) on July 25.